Sangamo Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on the stock and has a $10.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Patrick Trucchio has given his Buy rating due to a combination of factors tied to Sangamo’s lead Fabry gene therapy and key regulatory milestones. He highlights that Sangamo is close to completing its Biologics License Application for isa-vec, with nonclinical and clinical components already submitted and the final CMC module targeted for summer 2026, contingent on securing a commercialization partner to fund remaining BLA-readiness work.
He also underscores that recent STAAR Phase 1/2 data presented at WORLDSymposium show sustained renal function benefits over 104 weeks that diverge from the typical decline seen in Fabry patients on current treatments, reinforcing the therapy’s disease-modifying potential. In his view, successful partnering, BLA completion, and a potential commercial launch in early 2027 could unlock substantial value, supporting a Buy recommendation and a $10 price target despite modestly trimming the risk-adjusted contribution of isa-vec to $2 per share.
Trucchio covers the Healthcare sector, focusing on stocks such as Gossamer Bio, Atai Beckley N.V., and Alnylam Pharma. According to TipRanks, Trucchio has an average return of 23.9% and a 46.03% success rate on recommended stocks.